Tumor Biology

, Volume 37, Issue 10, pp 14321–14328 | Cite as

HSP90B1 overexpression predicts poor prognosis in NSCLC patients

  • YiRong Xu
  • ZhenWen Chen
  • GuangHeng Zhang
  • YanFeng Xi
  • RuiFang Sun
  • XiaoGang Wang
  • WenYan Wang
  • Fei Chai
  • XiongFeng Li
Original Article


Non-small cell lung cancer (NSCLC) accounts for 85 % of lung cancer-related mortality worldwide. The heat shock protein 90B1 (HSP90B1) and DNA damage-inducible transcript 3 (DDIT3) are endoplasmic reticulum stress-related proteins that are associated with many malignancies. However, the roles of two proteins on NSCLC remain uncovered. To investigate the correlation between the expressions of HSP90B1 and DDIT3 and clinicopathological parameters of NSCLC as well as the significance of prognosis in NSCLC, a total of 143 NSCLC tissue samples and 45 control tissues samples were assessed. NSCLC patients were followed up from the day of surgery and ended by March 2014. The expressions of HSP90B1 and DDIT3 proteins were detected in all paraffin-embedded biopsy samples by immunochemistry. The HSP90B1 was highly expressed (65.2 %) in the 143 NSCLC patients, and its high expression was correlated with clinical stages (P = 0.001) and lymph node metastasis (P = 0.016). Similarly, DDIT3 was highly expressed in 43 (30.1 %) of 143 NSCLC patients, but only correlated with lymph node metastasis. Furthermore, Log-rank test suggested that high HSP90B1 expression may predict shorter survival (overall survival (OS)) and disease-free survival (DFS) for NSCLC patients. Cox model multivariate analyses indicated that HSP90B1 overexpression was an independent poor prognostic factor for both of OS and DFS. Therefore, HSP90B1 and DDIT3 may the potential biomarker to predict the NSCLC clinicopathological progress. Meanwhile, high HSP90B1 expression means poor prognosis, and HSP90B1 can be a promising prognosis factor for NSCLC.


NSCLC HSP90B1 DDIT3 Prognosis 



This work was supported by the Natural Science Foundation of Shanxi Science and Technology Department (2012011038-4) and by the Intramural Research Program of Fenyang College of Shanxi Medical University.

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S–e29S.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zinner R, Visseren-Grul C, Spigel DR, Obasaju C. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer. Int J Oncol. 2016;48(1):13–27.PubMedGoogle Scholar
  3. 3.
    Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics. 2005;86(6):627–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Li M, Xiao T, Zhang Y, Feng L, Lin D, Liu Y, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer. 2010;69(3):341–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5, and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015;12(3):256–63.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol. 2008;39(7):1042–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008;8:70.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Takahashi H, Wang JP, Zheng HC, Masuda S, Takano Y. Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis. Histol Histopathol. 2011;26(6):663–71.PubMedGoogle Scholar
  9. 9.
    Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 2005a;24(19):3470–81.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tsim S, O’ Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104(12):1767–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Maximus S, Nguyen DV, Mu Y, Calhoun RF, Cooke DT. Size of stage IIIA primary lung cancers and survival: a surveillance, epidemiology and end results database analysis. Am Surg. 2012;78(11):1232–7.PubMedGoogle Scholar
  12. 12.
    Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Chai F, et al. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer. Tumor Biol. 2015;36(11):9039–47.CrossRefGoogle Scholar
  13. 13.
    Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10(24):8465–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Baum RP, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187–94.PubMedPubMedCentralGoogle Scholar
  15. 15.
    She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen W, Zheng R, Zeng H, Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6(2):209–15.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Dubey A, Prajapati KS, Swamy M, Pachauri V. Heat shock proteins: a therapeutic target worth to consider. Vet World. 2015;8(1):46–51.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Marcinak SJ, Ron D. The unfolded protein response in lung disease. Proc Am Thorac Soc. 2010;7(6):356–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kato H, Nishitoh H. Stress responses from the endoplasmic reticulum in cancer. Front Oncol. 2015;5:93.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yang Y, Li Z. Roles of heat shock protein gp96 in the ER quality control: redundant or unique function? Mol Cells. 2005;20(2):173–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee JH, Kang KW, Kim JE, Hwang SW, Park JH, Kim SH, et al. Differential expression of heat shock protein 90 isoforms in small cell lung cancer. Int J Clin Exp Pathol. 2015;8(8):9487–93.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Kim YS, Alarcon SV, Lee S, Lee MJ, Glaccone G, Neckers L, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 2009;9(15):1479–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 2012;76(1):26–31.CrossRefPubMedGoogle Scholar
  25. 25.
    Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823(3):742–55.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim KM, TK Y, Chu HH, Park HS, Jang KY, Moon WS, et al. Expression of ER stress and autophagy-related molecules in human non-small cell lung cancer and premalignant lesions. Int J Cancer. 2012;131(4):E362–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee CY, Lee MG, Choi KC, Kang HM, Chang YS. Clinical significance of GADD153 expression in stage I non-small cell lung cancer. Oncol Lett. 2012;4(3):408–12.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • YiRong Xu
    • 1
  • ZhenWen Chen
    • 1
  • GuangHeng Zhang
    • 1
  • YanFeng Xi
    • 2
  • RuiFang Sun
    • 2
  • XiaoGang Wang
    • 1
  • WenYan Wang
    • 1
  • Fei Chai
    • 1
  • XiongFeng Li
    • 1
  1. 1.Department of PathologyShanxi Medical University FenYang CollegeFenyangChina
  2. 2.Department of PathologyShanxi Tumor Hospital (Shanxi Institute of Oncology)TaiyuanChina

Personalised recommendations